Large inguinal synovial sarcoma mimics a vascular lesion: A case report and literature review

Wei-Chieh Chen a,1, Po-Chien Wu b,1, Chun-Yu Lin c, Ting-En Tai a,∗

a Department of Urology, Taipei Medical University Hospital, No. 252, Wuxing Street, Taipei, 110, Taiwan
b Department of Medical Education, Taipei Veterans General Hospital, 112, Taiwan
c Department of Medical Imaging, Taipei Medical University Hospital, No. 252, Wuxing Street, Taipei, 110, Taiwan

1. Introduction

Synovial sarcoma (SS) is a high-grade soft tissue sarcoma (STS) predominantly found near large joints in the extremities. SS can occur at any age, but it commonly occurs in teenagers and young adults aged 15–40 years [1]. The t(X;18)(p11;q11) chromosomal translocation results in SS18 gene rearrangement and the formation of the SYT-SSX fusion protein in SS [2]. From a histological perspective, SS is monophasic or biphasic, which presents a spindle-cell component with a variable degree of epithelial differentiation. Factors such as tumor size, histological subtype, metastases, and lymph node involvement affect the prognosis of patients with SS.

Numerous unusual locations of SS have been reported and confirmed by using molecular and immunohistochemistry techniques. Cases of SS primarily originating in inguinal areas are rare in English language literature [3]. Many lesions can attribute to groin tumor. The initial signs and symptoms of SS is hard to distinguish from other lesions. There is no standard treatment for inguinal SS. Herein, we reported a rare case of large inguinal SS and we reviewed updated information on multimodal therapy of STS.

2. Presentation of case

A 72-year-old man presented with a right inguinal progressively enlarged mass existing for 5 years. The tumor surface became ulcerative and painful with active bleeding for 2 weeks after he hit against a desk at right groin tumor (Fig. 1). Physical examination revealed a 15cm × 15cm large hard mass with ulcerative wound and tenderness. His medical history was unre-

https://doi.org/10.1016/j.cscr.2020.10.050
2210-2612/© 2020 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. (A) Right inguinal large mass with ulcerative wound and bleeding. (B) Gross appearance of the tumor after surgical resection.

Fig. 2. (A, B) Non-contrast CT image revealed a large right inguinal tumor with heterogeneous density (C, D) Contrast-enhanced CT image displayed vascular like lesions inside the tumor, raising the suspicion of pseudoaneurysm or active bleeding (white arrow).

remarkable. Laboratory examination showed normocytic anemia (red blood cell count: 2.59 × 10^6 uL; hemoglobin level: 8.9 g/dL; and hematocrit level: 26.2%). Ultrasound examination revealed a heterogeneous mass, diameter up to 15 cm, with abundant blood supply, as assessed by Doppler mode. Computed tomography (CT) revealed a well-circumscribed right inguinal heterogeneous tumor, measuring up to 15 cm, with a vivid enhanced area, implying the possibility of vascular lesion (Fig. 2). Angiography was performed for checking up the possibility of pseudoaneurysm or active bleeding. However, pelvic angiography only detected a hypervascular tumor with blood supply originating from right external iliac artery and inferior epigastric artery (Fig. 3). Biopsy was suggested but patient refused for high risk of bleeding. Thus, we performed surgical tumor resection with negative surgical margin. During the operation, a 15 cm × 12 cm × 5 cm tumor was resected, which was adherent to right spermatic cord without invasion.

Microscopically, the tumor was composed of spindle-to-ovoid tumor cells with areas of tubular glandular structures. More rounded cells and increased mitotic activity were also observed in poorly differentiated areas (Fig. 4). Immunohistochemically, the tumor cells were positive for transducin-like enhancer protein 1 and cytokeratin and focally positive for BCOR. The tumor cells were negative for S100 and SOX10. Molecular analysis conducted through fluorescence in situ hybridization (FISH) showed SS18 gene rearrangement. According to these findings, a primary biphasic SS
was diagnosed. He recovered well in the postoperative course without major complications.

The patient refused adjuvant radiation or chemotherapy owing to personal reasons. He had been followed up in clinic for 12 months, and no recurrence was observed.

3. Discussion

SS constitutes 5%–10% of STS. Despite its name, SS can originate from different organs, such as large joints, heart, lung, and abdominal wall. The most primary sites are extremities (68.7%) and trunk (15.7%) [4]. The cellular origin of SS is disordered mesenchymal stem cells that have undergone self-renewal dysregulation mediated by the SS18-SSX fusion protein [5]. SS has been reported to frequently affect adolescents and young adults with a median age of 35 years, with slight male predominance [4]. The 5-year survival rate ranges from 36% to 76%. A study demonstrated that female sex, nonblack race, extremity tumor, localized tumor, and tumor size smaller than 5 cm were associated with longer survival. The most metastatic sites are lung and bone [6].

Treatment options for SS include surgery, chemotherapy, radiotherapy, targeted therapy, and novel therapies. Wide-margin surgical resection remains the essential treatment for localized tumors. However, no consensus exists regarding the systemic treatment for SS. Recent studies have adequately discussed insight into neoadjuvant chemotherapy. Le Cesne et al. pooled two phase III clinical trials and revealed that adjuvant chemotherapy provided no overall survival or relapse-free survival benefits in completely resected SS [7]. A phase II trial focused on perioperative ifosfamide and doxorubicin for high-grade STS, which included 20 patients with SS, reported that the 5-year overall survival rate was 82.6% [8]. Pazopanib, a multitargeted tyrosine kinase inhibitor, was approved for STS treatment. In the PALETTE trial, pazopanib showed progression-free survival benefit in patient with metastatic STS, including those with SS [9]. Novel therapies targeting molecular and genetic pathways of SS are under research. A phase I trial of an SYT-SSX-derived peptide vaccine in six patients with SS was conducted in 2005 [10]; the trial demonstrated that the vaccine was well tolerated by all patients and it stabilized the disease in one patient. Recent studies have reported that retinoid acid and its derivatives inhibited growth signals and induced differentiation of SS cell lines both in vitro and in vivo, which could be a potential molecular target for treating SS [11]. A phase II trial of an epidermal growth factor receptor inhibitor was conducted on patients with SS who exhibited EGFR overexpression. Adjuvant radiation therapy can be administered through various approaches, including external beam therapy, brachytherapy, and intensity-modulated radiation therapy. Radiation therapies increased local control rates in patients with high-grade SS irrespective of ways of radiation therapy [12].

Four studies reporting inguinal SS in the literature were reviewed (Table 1). Hiede et al. [13] presented one case of SS in groin and no evidence of recurrence after surgical resection. Naito et al. [14] reported a typical biphasic-type SS from femoral neck, who had similar manifestations as our case. Open biopsy showed hemoptoma and angiography revealed abundant tumor blood supply from external iliac artery. No recurrence was observed after neoadjuvant chemo–radiotherapy and surgical resection. Xu et al. [3] reported a 68-year-old woman of inguinal monophasic synovial sarcoma with poor prognosis. Lung and spleen metastasis were noted 15 months after surgical resection, and she died of disease progression after 24-month follow-up. Wang et al. [15] reported a 53-year-old man with SS originating from spermatic cord. There is no evidence of recurrence after radical orchectomy and adjuvant chemotherapy for 36-month follow-up.

In our case, the initial impressions of large inguinal tumor were hemoloma or pseudoaneurysm. Preoperative angiography assisted in differentiating the lesion, evaluating tumor vessels, and preventing bleeding by embolization. We did not perform embolization in our patient due to high risk of nontargeted embolization to abdominal skin. Our patient recovered satisfactorily after surgical excision without major complications. We suggested adjuvant chemoradiotherapy, but the patient refused due to personal reasons. There was no evidence of recurrence for 12 months follow-up.

4. Conclusion

In conclusion, this is the first case report of biphasic SS in inguinal region. Various manifestations and rarity of SS lead us to have the first impression of vascular lesion. Our study demonstrated diagnostic image, surgical views, and treatment options for SS. Complete surgical resection is main treatment. Additionally, we reviewed and summarized reported cases of inguinal SS. Additional case reports and studies are warranted to achieve a clearer understanding of diagnoses and treatments of SS in groin.
Table 1
Details of primary inguinal synovial sarcoma in literature review.

| Study                  | Age | Sex   | Management                        | Diagnosis               | Follow up                                      |
|------------------------|-----|-------|-----------------------------------|-------------------------|-----------------------------------------------|
| Heide et al. 1988 [13] | 47  | Male  | Surgical excision                 | SS in groin             | No evidence of recurrence after 56-month follow-up |
| Naito et al. 2000 [14] | 19  | Female| Neoadjuvant chemoradiotherapy + surgical excision | Biphasic SS from femoral neck | No evidence of recurrence after 24-month follow-up |
| Xu et al. 2010 [3]     | 68  | Female| Surgical excision                 | Monophasic SS in groin  | Lung and spleen metastases were observed 15 months after surgery, and patient died 24 months after surgery |
| Wang et al. 2015 [15]  | 53  | Male  | Surgical excision + adjuvant chemoradiotherapy | Monophasic SS of spermatic cord | No evidence of recurrence after 36-month of follow-up |

Declaration of Competing Interest
The authors report no declarations of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Ethical approval
The research related to human use has been complied with all the relevant national regulations, institutional policies, and has been approved by the Research Ethical Committee of Taipei Medical University Hospital (Case number: N201910051).

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images.

Author contribution
Data collection: Wei-Chieh Chen and Po-Chien Wu.
Writing the paper: Po-Chien Wu and Ting-En Tai.
Editing the paper: Wei-Chieh Chen and Chun-Yu Lin.

Registration of research studies
1. Name of the registry: Research Ethical Committee of Taipei Medical University Hospital.
2. Unique identifying number or registration ID: N201910051.

Guarantor
Ting-En Tai.

Provenance and peer review
Not commissioned, externally peer-reviewed.

Acknowledgements
This manuscript was edited by Wallace Academic Editing.

References
[1] Z. Burningham, et al., The epidemiology of sarcoma, Clin. Sarcoma Res. 2 (2012) 14.
[2] J.D. Pfeifer, et al., Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics? Histopathology 37 (2000) 485–500.
[3] J. Xu, et al., Malignant inguinal monophasic synovial sarcoma: report of a case and review of the literature, World J. Surg. Oncol. 8 (2010) 102.
[4] A. Ferrari, et al., Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database, Pediatr. Blood Cancer 57 (2011) 943–949.
[5] N. Naka, et al., Synovial sarcoma is a stem cell malignancy, Stem Cells 28 (2010) 1119–1131.
[6] M. Vletterie, et al., Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity, Eur. J. Cancer 58 (2016) 62–72.
[7] A. Le Cesne, et al., Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials, Ann. Oncol. 25 (2014) 2425–2432.
[8] J.M.E. Desar, E.D.G. Fleuren, W.T.A. van der Graaf, Systemic treatment for adults with synovial sarcoma, Curr. Treat. Options Oncol. 19 (2018) 13.
[9] W.T. van der Graaf, et al., Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet 379 (2012) 1879–1886.
[10] S. Kawaguchi, et al., Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma, J. Transl. Med. 3 (2005) 1.
[11] M.W. Room, et al., In vitro modulation of MMP-2 and MMP-9 in adult human sarcoma cell lines by cytokines, inducers and inhibitors, Int. J. Oncol. 43 (2013) 1787–1798.
[12] B. O'Sullivan, et al., Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial, Lancet 359 (2002) 2235–2241.
[13] H.J. van der Heide, et al., Synovial sarcoma: oncological and functional results, Eur. J. Surg. Oncol. 24 (1998) 114–119.
[14] N. Naito, et al., Synovial sarcoma with a large hematoma in the inguinal region, Arch. Orthop. Trauma Surg. 120 (2000) 533–534.
[15] G.C. Wang, et al., Clinical features in a man with primary synovial sarcoma of the spermatic cord, Asian J. Androl. 17 (2015) 343–344.

Open Access
This article is published Open Access at scienceDirect.com. It is distributed under the iJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.